Core Insights - Zai Lab's partner Amgen has halted the evaluation of bemarituzumab in combination with chemotherapy and nivolumab for first-line gastric cancer in the FORTITUDE-102 clinical trial due to insufficient efficacy observed in interim analysis by an independent data monitoring committee [2][3] - The FORTITUDE-102 trial was intended to assess the treatment effects of bemarituzumab, a monoclonal antibody targeting FGFR2b, in combination with chemotherapy and nivolumab [2] - The termination of FORTITUDE-102 affects Zai Lab's strategic plans in the gastric cancer space, especially following the disappointing results from the FORTITUDE-101 trial [3] Summary by Sections Clinical Trial Results - The independent data monitoring committee concluded that the therapy did not demonstrate sufficient efficacy, leading to Amgen's decision to stop the trial [2] - The FORTITUDE-101 trial had previously shown significant statistical and clinical improvement in overall survival compared to chemotherapy alone during interim analysis, but this benefit diminished in the final analysis [2] Future Implications - With the termination of FORTITUDE-102, Zai Lab's strategy for gastric cancer treatment is now uncertain, as the data from this trial was expected to be released by the end of 2025 or early 2026 [3] - Zai Lab has stated it will continue to collaborate closely with Amgen and provide further updates as appropriate [3]
再鼎医药胃癌新药临床数据不及预期